Viveve Medical

Viveve Medical, Inc. engages in the design, development, manufacture, and marketing of platform medical technology. It offers cryogen-cooled monopolar radio frequency technology, which delivered through a radiofrequency generator, hand piece and treatment tip. The Viveve system is a non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company was founded on March 3, 1987 and is headquartered Englewood, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viveve Medical (NASDAQ: VIVE ) stock is falling hard on Tuesday after releasing results from the company's latest clinical trial. That trial covers the use of the Viveve treatment for women suffering from stress urinary incontinence.

Why Is Viveve Medical (VIVE) Stock Down 69% Today?

Study's primary efficacy endpoint was not achieved at 12 months post-treatment Company has implemented a reduction in force Company will seek strategic alternatives and will be delisted from Nasdaq ENGLEWOOD, CO / ACCESSWIRE / January 17, 2023 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced topline result from the U.S. Pivotal PURSUIT clinical trial. PURSUIT was a multicenter, randomized, double-blinded, sham-controlled U.S. study to evaluate the safety and efficacy of the Viveve treatment for SUI in women.

Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence

Topline results of the 12-month primary efficacy endpoint anticipated in January 2023 Positive results may support a de novo marketing application for a new U.S. indication for treatment of stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / December 15, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and treatment of female stress urinary incontinence, today announced the completion of final 12-month post-treatment follow-up visits in its landmark U.S. PURSUIT clinical trial for the treatment of stress urinary incontinence (SUI) in women. A total of 415 patients were enrolled in the trial, and 342 patients completed 12-month follow-up visits.

Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded

Patent further strengthens Viveve's novel dual-energy technology intellectual property portfolio as company plans for completion of pivotal PURSUIT clinical trial ENGLEWOOD, CO / ACCESSWIRE / December 1, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11511110 covering Viveve's treatment to address SUI in women.

Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

Viveve Medical, Inc. (NASDAQ:VIVE ) Q3 2022 Results Conference Call November 10, 2022 5:00 PM ET Company Participants Jeannie Swindle - Senior Director, Corporate Communications Scott Durbin - CEO Jim Robbins - SVP, Finance and Administration Operator Good afternoon. Welcome to the Viveve Third Quarter 2022 Financial Results and Corporate Update Conference Call.

Viveve Medical, Inc. (VIVE) Q3 2022 Earnings Call Transcript

Total revenue of $1.7 million in Q3 including sale of 3,100 disposable treatment tips PURSUIT clinical trial completion expected by year-end Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO / ACCESSWIRE / November 10, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today reported financial results for the quarter ended September 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today. "During the third quarter of 2022, we continued to make great progress in the final phase of our pivotal U.S. PURSUIT clinical trial for the treatment of female stress urinary incontinence.

Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / October 27, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its third quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 10, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.

Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022

Patent issuance further strengthens Viveve's intellectual property portfolio for the treatment of female stress urinary incontinence ENGLEWOOD, CO / ACCESSWIRE / October 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application 16/454,578 covering Viveve's unique dual-energy treatment to address SUI in women. The pending issuance of the new SUI patent further strengthens the Company's intellectual property portfolio in advance of the planned completion of its U.S. pivotal PURSUIT clinical trial by the end of the year and reporting of topline results in early 2023.

Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

ENGLEWOOD, CO / ACCESSWIRE / September 22, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Ladenburg Thalmann Healthcare Conference, September 29, 2022, in New York City. Mr. Durbin will deliver the Viveve corporate presentation and provide an update on progress of the Company's SUI clinical development program.

Viveve to Participate in Ladenburg Thalmann Healthcare Conference

ENGLEWOOD, CO / ACCESSWIRE / September 15, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Alliance Global Partners Virtual MedTech Conference, September 21, 2022. Mr. Durbin will provide an update on Viveve's operations including progress of its SUI clinical development program and will meet with investment community members during the virtual conference.

Viveve to Participate in Alliance Global Partners Virtual MedTech Conference

ENGLEWOOD, CO / ACCESSWIRE / September 1, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12 - 14, 2022.

Viveve to Participate in H.C. Wainwright 24th Annual Global Investment Conference

Viveve Medical, Inc. (NASDAQ:VIVE ) Q2 2022 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Jeannie Swindle - Senior Director, Corporate Communications Jim Robbins - SVP, Finance and Administration Scott Durbin - CEO Conference Call Participants Operator Good afternoon, and welcome to the Viveve Second Quarter 2022 Financial Results and Corporate Update Conference Call. [Operator Instructions] Please note, this event is being recorded.

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q2 2022 Results - Earnings Call Transcript

Total revenue of $1.8 million in Q2 including sale of 2,850 disposable treatment tips PURSUIT clinical trial follow-up visit completion anticipated by year end Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO / ACCESSWIRE / August 11, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today reported financial results for the quarter ended June 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today. "During the second quarter of 2022, we continued to advance our stress urinary incontinence (SUI) clinical development program.

Viveve Reports Second Quarter 2022 Financial Results and Provides Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / July 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its second quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, August 11, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.

Viveve to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 11, 2022

ENGLEWOOD, CO / ACCESSWIRE / July 12, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that the Taiwan Intellectual Property Office (TIPO) recently issued Taiwan Patent No. I766557 for Viveve's dual-energy technology.

Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan

ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright Global Investment Conference, May 23 - 26, 2022.

Viveve to Participate in H.C. Wainwright Global Investment Conference

Durbin recognized for second consecutive year for leading development of Viveve's innovative technology for treatment of stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / May 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, announced today that Scott Durbin, the Company's Chief Executive Officer, has been named by Healthcare Technology Report as one of The Top 50 Healthcare Technology CEOs of 2022. Mr. Durbin was also named one of the Top 50 Healthcare Technology CEOs in 2021.

Viveve CEO Scott Durbin Named Among Top 50 Healthcare Technology Leaders of 2022 by Healthcare Technology Report

Viveve Medical, Inc. (NASDAQ:VIVE ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Jeannie Swindle - Senior Director, Corporate Communications Jim Robbins - Senior Vice President, Finance and Administration Scott Durbin - Chief Executive Officer Conference Call Participants Operator Good afternoon, and welcome to the Viveve First Quarter 2022 Financial Results and Corporate Update Conference Call. All participants will be in a listen-only mode.

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q1 2022 Results - Earnings Call Transcript

Total revenue of $1.6 million in Q1 including sale of 2,750 consumable treatment tips PURSUIT trial top-line results anticipated at end of 2022 Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO / ACCESSWIRE / May 12, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended March 31, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today. "During the first quarter of 2022, we continued the focus on advancing our stress urinary incontinence (SUI) clinical development program.

Viveve Reports First Quarter 2022 Financial Results and Provides Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / April 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, May 12, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.

Viveve to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 12, 2022

Viveve Medical Inc. (VIVE) CEO Scott Durbin on Q4 2021 Results - Earnings Call Transcript

Reported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growth Enrollment completed in U.S. pivotal PURSUIT trial for stress urinary incontinence and 12-month post treatment follow-up visits underway PURSUIT top-line results anticipated at end of 2022 Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO / ACCESSWIRE / March 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the year ended December 31, 2021. The Company will provide a corporate update on its scheduled conference call at 5:00 PM ET today.

Viveve Reports Full Year 2021 Financial Results and Provides Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / March 3, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its full year 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, March 17, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.

Viveve to Report Full Year 2021 Financial Results and Provide Corporate Update on March 17, 2022

ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright BIOCONNECT Conference, January 10 - 13, 2022.

Viveve to Participate in H.C. Wainwright BIOCONNECT Conference

Major milestone achieved in Company's advance toward a new U.S. SUI indication ENGLEWOOD, CO / ACCESSWIRE / December 14, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, announced today that it has completed enrollment in its pivotal PURSUIT clinical trial to assess the efficacy and safety of the Viveve procedure in the treatment of stress urinary incontinence (SUI) in women. Positive results from the highly powered study could support an FDA approval for a new indication for Viveve's dual-energy, noninvasive, single session treatment in the U.S. "We are very pleased to have completed enrollment in our landmark PURSUIT trial, which represents a major milestone and another example of our progress in advancing this important clinical program.

News for Viveve Medical Stock (VIVE)